Published on 05:14 PM, May 03, 2016

Johnson & Johnson hit with $55m damages in talc cancer case

A bottle of Johnson & Johnson Baby Powder is seen in a photo illustration taken in New York, February 24, 2016. Johnson & Johnson said the safety of talc was supported by decades of scientific evidence. Photo: Reuters

Pharmaceutical firm Johnson & Johnson (J&J) has been ordered to pay more than $55m (£40m) in compensation to an American woman who says its talcum powder caused her ovarian cancer.

Gloria Ristesund, 62, said she used J&J talc-based powder products on her genitals for decades.

The company - which faces about 1,200 similar claims - insists its products are safe and says it will appeal.

Researchers say links with ovarian cancer are unproven.

In February, Johnson & Johnson paid $72m (£51m) in a similar case.

Damages

Ristesund was diagnosed with ovarian cancer in 2011 and had to undergo a hysterectomy and related surgeries. Her cancer is now in remission.

Following a three-week trial in a Missouri state court, she was awarded $5m in compensatory damages and $50m in punitive damages.

Jere Beasley, whose firm represents Ristesund, said his client was gratified with the verdict. The jury's decision should "end the litigation", he said, and force J&J to settle the remaining cases.

A J&J spokeswoman said the verdict contradicted 30 years of research supporting the safety of cosmetic talc.

Carol Goodrich said the company intends to appeal and will keep defending its products' safety.

Other cases pending

The case follows another one in February, in which Johnson & Johnson was ordered to pay $72m to the family of a woman who claimed her death was linked to use of the company's Baby Powder talc.

Jackie Fox from Birmingham, Alabama died of ovarian cancer last year, aged 62, having used the talc for decades.

Her family argued that the firm knew of talc risks and failed to warn users.

J&J is appealing against that verdict, which sparked renewed interest in talc-powder lawsuits. Lawyers accuse J&J of failing to warn that talc was linked to an increased risk for ovarian cancer - a claim J&J denies. There are 1,200 other cases pending.

J&J shares were down 18 cents in after-hours trading to $112.57.